Performance status-2 - Symptomatic, 50 in bed - Page 5 of 12 Posts on Medivizor
Navigation Menu

Performance status-2 – Symptomatic, 50 in bed Posts on Medivizor

Are end-of-treatment PET scans necessary?

Are end-of-treatment PET scans necessary?

Posted by on Jan 6, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether end-of-treatment PET scans could be left out if the mid-treatment scans were negative (no cancer activity). The authors concluded that the end-of-treatment scans were essential, even in patients with negative interim results. Some background Positron emission tomograpy (PET) scans are used to...

Read More

Radiation therapy after stem-cell transplantation is safe and effective for relapsed- or refractory Hodgkin lymphoma

Radiation therapy after stem-cell transplantation is safe and effective for relapsed- or refractory Hodgkin lymphoma

Posted by on Jan 2, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed whether patients with relapsed- or refractory Hodgkin Lymphoma should be treated with radiation therapy. The authors concluded that radiation therapy was safe and prevented the return of the disease in certain patients. Some background Hodgkin lymphoma is a cancer of the lymph system. It is a...

Read More

Bleomycin lung toxicity is not associated with the risk of radiation lung injury in Hodgkin lymphoma

Bleomycin lung toxicity is not associated with the risk of radiation lung injury in Hodgkin lymphoma

Posted by on Dec 24, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether or not there was an increased risk of radiation pneumonitis (RP, radiation-induced lung injury) in Hodgkin lymphoma patients treated with the chemotherapy bleomycin. The authors concluded that there was no association between bleomycin lung effects and RP. Some background...

Read More

Searching for small-cell lung cancer patients to test pembrolizumab combined with chemotherapy and radiation

Posted by on May 23, 2016 in Lung cancer | 0 comments

In a nutshell This phase 1 trial aims to determine the dosage of the anti-cancer drug pembrolizumab (Keytruda, or MK-3475) and whether it is effective at treating small-cell lung cancer (SCLC) when combined with both chemotherapy and radiation therapy. The main outcome of the trial will be the maximum tolerated dose (MTD – the highest dose of a...

Read More

Dealing with cancer pain: Low-dose morphine examined

Dealing with cancer pain: Low-dose morphine examined

Posted by on Feb 6, 2016 in Breast cancer | 0 comments

In a nutshell This study compared weak opioids and low-dose morphine in providing pain relief for moderate cancer pain. Researchers concluded that low-dose morphine is more suitable as pain management for moderate cancer pain than weaker pain relievers. Some background The guidelines for cancer pain relief developed by the World Health...

Read More

Dealing with cancer pain: Low-dose morphine examined

Dealing with cancer pain: Low-dose morphine examined

Posted by on Feb 6, 2016 in Lung cancer | 0 comments

In a nutshell This study compared weak opioids and low-dose morphine in providing pain relief for moderate cancer pain. Researchers concluded that low-dose morphine is more suitable as pain management for moderate cancer pain than weaker pain relievers. Some background The guidelines for cancer pain relief developed by the World Health...

Read More

Benefits of preventive radiation therapy to the head in stage III-N2 non-small cell lung cancer

Benefits of preventive radiation therapy to the head in stage III-N2 non-small cell lung cancer

Posted by on Jun 14, 2015 in Lung cancer | 0 comments

In a nutshell The authors evaluated the benefits of preventive radiation therapy in patients with non-small cell lung cancer (NSCLC) who have high risk of developing brain metastases (spreading of cancer from the lungs to the brain). Some background NSCLC is the most common type of lung cancer, accounting for 85% of all lung cancers. In...

Read More

Maintenance therapy does not impair subsequent treatment with pemetrexed in metastatic lung cancer

Posted by on Feb 23, 2015 in Lung cancer | 0 comments

In a nutshell The authors aimed to determine whether previous maintenance therapy with gemcitabine or erlotinib impaired pemetrexed treatment.  Some background Maintenance therapy is the ongoing use of chemotherapy  or another treatment given to help the primary treatment succeed and prevent cancer recurrence. Two drugs have been...

Read More